

# Meta-Analysis of Probiotics for the Prevention of Antibiotic Associated Diarrhea and the Treatment of *Clostridium difficile* Disease

Lynne V. McFarland, Ph.D.<sup>1,2</sup>

<sup>1</sup>Department of Health Services Research and Development, Veterans Administration Puget Sound Health Care System, Seattle, Washington, and <sup>2</sup>Department of Medicinal Chemistry, University of Washington, Seattle, Washington

- CONTEXT:** Antibiotic-associated diarrhea (AAD) is a common complication of most antibiotics and *Clostridium difficile* disease (CDD), which also is incited by antibiotics, is a leading cause of nosocomial outbreaks of diarrhea and colitis. The use of probiotics for these two related diseases remains controversial.
- OBJECTIVE:** To compare the efficacy of probiotics for the prevention of AAD and the treatment of CDD based on the published randomized, controlled clinical trials.
- DATA SOURCES:** PubMed, Medline, Google Scholar, NIH registry of clinical trials, metaRegister, and Cochrane Central Register of Controlled Trials were searched from 1977 to 2005, unrestricted by language. Secondary searches of reference lists, authors, reviews, commentaries, associated diseases, books, and meeting abstracts.
- STUDY SELECTION:** Trials were included in which specific probiotics given to either prevent or treat the diseases of interest. Trials were required to be randomized, controlled, blinded efficacy trials in humans published in peer-reviewed journals. Trials that were excluded were pre-clinical, safety, Phase 1 studies in volunteers, reviews, duplicate reports, trials of unspecified probiotics, trials of prebiotics, not the disease being studied, or inconsistent outcome measures. Thirty-one of 180 screened studies (totally 3,164 subjects) met the inclusion and exclusion criteria.
- DATA EXTRACTION:** One reviewer identified studies and abstracted data on sample size, population characteristics, treatments, and outcomes.
- DATA SYNTHESIS:** From 25 randomized controlled trials (RCTs), probiotics significantly reduced the relative risk of AAD (RR = 0.43, 95% CI 0.31, 0.58,  $p < 0.001$ ). From six randomized trials, probiotics had significant efficacy for CDD (RR = 0.59, 95% CI 0.41, 0.85,  $p = 0.005$ ).
- CONCLUSION:** A variety of different types of probiotics show promise as effective therapies for these two diseases. Using meta-analyses, three types of probiotics (*Saccharomyces boulardii*, *Lactobacillus rhamnosus* GG, and probiotic mixtures) significantly reduced the development of antibiotic-associated diarrhea. Only *S. boulardii* was effective for CDD.

(Am J Gastroenterol 2006;101:812–822)

Antibiotic-associated diarrhea (AAD) is a common complication of antibiotic use. The frequency of AAD can be high (26–60%) during hospital outbreaks or moderate (13–29%) during endemic periods and is relatively infrequent in outpatient settings (<0.1%) (1–3). Risk factors for AAD include broad-spectrum antibiotics, host factors (age, health status, gender), hospitalization status, and exposure to nosocomial pathogens (2, 4). AAD usually occurs 2–8 wk after exposure to antibiotics as a result of disrupting intestinal microflora. One of the roles of intestinal microflora is to act as a protective barrier that resists the colonization of intestinal pathogens (5). Without this protective bar-

rier, patients are susceptible to infection by opportunistic pathogens.

Hospitalized patients exposed to antibiotics may develop *Clostridium difficile* disease (CDD). Recently, this pathogen caused nosocomial outbreaks in Canadian hospitals that resulted in over 100 deaths (6). Consequences of AAD and CDD include extended hospital stays (3–7 days), increased rates of subsequent infections (20–65%), higher hospital costs (up to \$1 billion/yr) and 2–3 times increased rates of mortality (7–11).

Current therapies for AAD are lacking. Strategies to date include discontinuing the inciting antibiotic, restricting the

use of high-risk antibiotics and specific antibiotic treatments if the etiology is known. For CDD, 80% respond well to the initial treatment of vancomycin or metronidazole. The remaining 20% may develop subsequent episodes of CDD, which may persist over several years, despite repeated antibiotic treatments (9).

Probiotic therapy is well suited to these two types of microbial induced diseases. Probiotics assist in reestablishing the disrupted intestinal microflora, enhancing immune responses and clearing pathogens and their toxins from the host (12–14). Research using probiotics has been reported for the past 28 yr, but the studies have been variable in trial design, type of probiotic, had differing doses and durations of treatment, and thus have yielded contradictory results. The lack of definitive evidence regarding efficacy and safety is limiting the use of this type of treatment strategy. There is a growing interest in probiotics for the treatment of AAD and CDD due to the wide availability of probiotics as dietary supplements and the concern over recent outbreaks of severe CDD in Canada and the United Kingdom (6, 15). Two meta-analyses done in 2002 presented results on only 11 trials and failed to discuss possible reasons for the conflicting findings and did not present detailed study information (16, 17). A recent Cochrane review on treatments for CDD did not include probiotics (18). The need for a meta-analysis of probiotics for these two antibiotic associated diseases is apparent.

## METHODS

### Objectives

The objectives of this meta-analysis are to assess the efficacy and safety of probiotics for (i) the prevention of AAD and (ii) the treatment of CDD.

### Criteria for Study Selection

Abstracts of all citations and retrieved studies were reviewed and rated for inclusion. Full articles were retrieved if specific treatments were given to either prevent or treat the disease of interest. Inclusion criteria include randomized, controlled, blinded efficacy trials in humans published in peer-reviewed journals. Exclusion criteria include pre-clinical studies, case reports or case series, Phase 1 safety studies in volunteers, reviews, duplicate reports, trials of unspecified probiotics, trials of prebiotics, not the disease being studied, or inconsistent outcome measures. External and internal validity is strengthened by including only randomized controlled trials (RCTs).

### Outcomes and Definitions

The primary outcome for AAD is defined as diarrhea ( $\geq 3$  loose stools/day for at least 2 days or  $\geq 5$  loose stools/48 h) within 2 months of antibiotic exposure (2, 11). The primary outcome of CDD is defined as a new episode of diarrhea associated with a positive culture or toxin (A or B) assay within 1 month exposure to antibiotics. The outcome for prevention of

CDD is a new episode of *C. difficile* positive diarrhea within 1 month of a previous CDD episode (19). Documentation of diarrhea is based on clinical assessment and self-report of symptoms by daily symptom diaries.

### Data Sources

PubMed, Medline, and Google Scholar were searched from 1977 to 2005 for articles unrestricted by language. Non-English articles were translated. Three on-line clinical trial registers were searched: Cochrane Central Register of Controlled Trials (<http://www.cochrane.org>), metaRegister of Controlled Trials (<http://www.controlled-trials.com/mrct>) and National Institutes of Health (<http://www.clinicaltrials.gov>). Secondary and hand searches of reference lists, authors, reviews, commentaries, associated diseases, books, and meeting abstracts were also performed. Six search terms for RCTs (RCT, human, blinding, Phase 2, Phase 3, efficacy) were combined with 15 terms for probiotics. Search terms included probiotics, microflora, antibiotics, *Clostridium difficile*, colitis, PMC, diarrhea, Saccharomyces, Lactobacilli, Bifidobacteria, Enterococci, Bacilli, VSL#3, synbiotics, and Lactinex. Search strategies were broad-based initially, then narrowed to the disease of interest (20). The procedure for this meta-analysis was designed as suggested by Egger *et al.* and MOOSE guidelines using clearly delineated parameters, *a priori* inclusion and exclusion criteria, and standardized data extraction methods (21–23).

### Data Extraction

Information on study design, methods, interventions, outcomes, adverse effects, and treatments was extracted from each article. Data on patient inclusion and exclusion criteria, number of completed subjects, attrition, treatment dose and duration, and outcome was extracted into a standardized table. In some cases, the primary or secondary author was contacted for data not reported in the original article. The data abstraction was completed individually, but verified using historic searches with two other researchers for previous review articles (24, 25). A few trials had multiple probiotic arms with a common control group. Each probiotic arm and control group was analyzed separately.

### Assessment of Methodological Quality

Studies that met the inclusion criteria were graded for quality using a scale reported by the U.S. Preventive Services Task Force (26). Quality of evidence is rated from 1 to 3 (poor, fair, and good) based on randomization, study design, sample size, generalizability, study biases, and outcome assessment. Study quality was not integrated with the model weights, as trials of poor quality were excluded from review and this practice is not uniformly recommended (27). Weights for this analysis are based solely on sample sizes.

### Statistical Analysis


Statistical analysis was performed using Stata software version 8.0 (Stata Corporation, College Station, TX). Relative

risks with 95% confidence intervals were computed as summary statistics. Heterogeneity across trials was evaluated using Cochran Q test based on pooled relative risks by the Mantel-Haenszel method. If the studies were homogeneous, a fixed-effects model was used and a pooled relative risk was calculated with the Mantel-Haenszel method for fixed effects. If the studies were heterogeneous a random effect was employed and a pooled relative risk was calculated using the DerSimonian and Laird method (28). If significant heterogeneity was detected, a subgroup analysis was conducted. *A priori* subgroups were by type of probiotic, dose and indication (AAD or CDD). A funnel plot as well as an adjusted rank correlation test using the Begg and Mazumdar method were used to assess publication bias (29, 30). *p* Values less than 0.05 were considered significant.

## RESULTS

### Overview of Included Studies

**AAD.** The literature search yielded 940 citations, of which 104 were selected from retrieval. Twenty-five (24%) of the screened articles met inclusion criteria and provided data on 2,810 treated patients with AAD. The number of patients in each of these studies was generally moderate (median, 79; range 18–388). A QUOROM (Quality of Reporting of Meta-analysis) flow diagram (Fig. 1) shows an overview of the study selection process (22).



**Figure 1.** QUOROM flow diagram of included and excluded studies. RCT indicates randomized, controlled trial.

**CDD.** The literature search yielded 940 citations, of which 76 were selected from retrieval. Only six (8%) of the screened articles met inclusion criteria and provided data on 354 treated patients with CDD. The number of patients in each of these studies was generally small (median, 25; range 15–138).

### Excluded Studies

**AAD.** Of the AAD studies, 79 failed to meet one or more of the inclusion criteria. Most were reviews or commentaries ( $n = 57$ ), pre-clinical or Phase 1 safety studies done in healthy volunteers ( $n = 11$ ) or had no control group ( $n = 4$ ). AAD was a *post hoc* outcome in three trials and one study failed to provide outcome data. Some studies were excluded because the type of probiotic was not specified (31, 32) or only a prebiotic (oligosaccharide with no living probiotic) was given as the intervention (33).

**CDD.** Of the CDD studies, 70 failed to meet one or more of the inclusion criteria. Most were reviews or commentaries ( $n = 41$ ), pre-clinical or Phase 1 safety studies done in healthy volunteers ( $n = 7$ ) or had no control group ( $n = 18$ ). Some studies were excluded because CDD was a *post hoc* outcome ( $n = 3$ ) or only a prebiotic (oligosaccharide with no living probiotic) was given as the intervention (34).

### Study Quality

The quality of the studies is presented in Tables 1 and 3, indicating generally good methodological quality. Most studies of poor quality were excluded from the data extraction in the preliminary steps of this study.

### Efficacy Studies

**AAD.** Twenty-five RCTs provided adequate data regarding efficacy in a total of 2,810 patients with AAD, as shown in Table 1. Of the 25 trials, 13 (52%) reported a significant reduction of AAD in the probiotic-treated group compared with the placebo group in their study. Twelve studies did not reject the null hypothesis of no difference in the incidence of AAD for probiotic treated *versus* controls.

These contradictory results may be due to differences in the study population enrolled, the type of probiotic, the dose of probiotic given, or the duration of treatment. Typically, these trials were done in adults given broad-spectrum antibiotics (64%), while 36% of the trials were done in children taking antibiotics. Of 16 RCTs of AAD in adult patients, 7 (44%) showed significant efficacy for probiotics. Of nine RCTs of AAD in children, six (67%) had significant efficacy. There was not a significant difference in efficacy of probiotics according to whether adults or children were enrolled (Fisher's  $p = 0.41$ ). The types of probiotics varied from single strains (*Saccharomyces boulardii*, *Lactobacillus rhamnosus* GG, *Bacillus clausii*, *Bifidobacterium longum*, *Clostridium butyricum* miyairir, *Lactobacillus acidophilus*, *Enterococcus faecium* SF68), to mixtures of two types of probiotic and to a synbiotic (a probiotic combined with a pre-biotic substance). Daily doses of probiotics ranged from  $1 \times 10^7$  to  $1 \times 10^{11}$ , with a mean of  $3 \times 10^9$ . Use of a high dose ( $\geq 10^{10}$ /day) of

**Table 1.** Description of 25 Randomized Controlled Trials of Probiotics for the Prevention of Antibiotic Associated Diarrhea

N	Subjects	Probiotic	Dose/Day	Txt Duration	Follow-Up	Probiotic-Treated			Control Group			Quality	Weight	Reference
						No. Failed	No. Cured	No. Cured	No. Failed	No. Cured	No. Cured			
388	Adults, b-lactam or tetracycline	SB	$4 \times 10^9$	1 wk	0	9 (4.5)	190	33 (17.5)	156	3	4.9	(35)		
180	Adults, varied	SB	$2 \times 10^{10}$	On abx	2 wk	11 (9.5)	105	14 (21.8)	50	3	4.9	(36)		
193	Adults, b-lactams	SB	$2 \times 10^{10}$	4 wk	7 wk	7 (7.2)	90	14 (14.6)	82	3	4.4	(37)		
246	Peds, varied	SB	$1 \times 10^{10}$	1-2 wk	2 wk	4 (3.4)	115	22 (17.3)	105	3	3.8	(38)		
69	Elderly, varied	SB	$4 \times 10^9$	2 wk	0	7 (21)	26	5 (13.9)	31	2	3.8	(39)		
43	<i>H. pylori</i> + 3 abx	SB	$5 \times 10^9$	7 days	0	1 (5)	21	6 (30)	15	2	1.7	(40)		
119	Peds, varied	LGG	$4 \times 10^{10}$	2 wk	12 wk	3 (5)	58	9 (16)	49	3	3.2	(41)		
188	Outpatient peds, varied oral abx	LGG	$1-2 \times 10^{10}$	10 days	0	7 (7.5)	86	25 (26)	70	3	4.6	(42)		
81	Hosp peds, varied	LGG	$1 \times 10^{10}$	Varied	0	3 (6.7)	42	12 (33.3)	24	2	3.4	(43)		
267	Hosp adults 70% b-lactam/varied	LGG	$2 \times 10^{10}$	2 wk	1 wk	39 (29.3)	94	40 (29.9)	94	3	6.1	(44)		
42	<i>H. pylori</i> + 3 abx	LGG	$6 \times 10^9$	7 days	0	1 (5)	20	6 (30)	15	2	1.7	(40)		
120	<i>H. pylori</i> + 3 abx	LGG	$1 \times 10^{10}$	2 wk	0	2 (3.4)	58	16 (26.6)	44	3	2.8	(45)		
100	<i>H. pylori</i> + 3 abx	BC	$6 \times 10^9$	2 wk	0	15 (30)	35	17 (34)	33	2	5.4	(46)		
20	Adults, clindamycin	BL	$5 \times 10^{10}$	21 days	0	4 (40)	6	7 (70)	3	2	4.4	(47)		
110	Peds, varied	CB	$1-4 \times 10^7$	6 days	0	6 (7)	77	16 (59)	11	2	4.5	(48)		
45	Adults, varied	EF	$1.5 \times 10^7$	7 days	0	2 (8.7)	21	6 (27)	16	2	2/6	(49)		
200	Adults with TB	EF	Ng	8 wk	0	5 (5)	95	18 (18)	82	3	4.1	(50)		
27	Adults amoxicillin	LA	$1.2 \times 10^8$	Varied	0	10 (83)*	2	10 (67)	5	2	5.9	(51)		
79	Hosp adults, ampicillin	Lactinex	$2 \times 10^9$	5 days	0	3 (8.3)	33	9 (21)	34	2	3.2	(52)		
38	Peds, amoxicillin	Lactinex	$2 \times 10^9$	10 days	0	10 (66)	5	16 (69.5)	7	2	5.8	(53)		
20	Adults, clindamycin	LABLa	$1 \times 10^{11}$	21 days	0	2 (20)	8	7 (70)	3	2	3.0	(47)		
42	<i>H. pylori</i> + 3 abx	LABL	$5 \times 10^9$	7 days	0	1 (5)	20	6 (30)	15	2	1.7	(40)		
77	Children, varied	BLST	$1 \times 10^7$	15 days	15 days	6 (16)	32	12 (31)	27	2	4.3	(54)		
98	Children, varied	LS FOS	$5.5 \times 10^8 + 250$ mg	10 days	0	14 (29)	34	31 (62)	19	2	5.7	(55)		
18	Infants 1-36 months on antibiotics	LABI	$6 \times 10^9$	7 days	0	3 (37.5)	5	8 (80%)	2	2	4.1	(56)		

N = number of subjects with evaluable outcome; SB = *Saccharomyces boulardii*; LGG = *Lactobacillus rhamnosus* GG; BC = *Bacillus clausii*; BL = *Bifidobacterium longum*; CB = *Clostridium butyricum* MIYAIRI; EF = *Enterococcus faecium* SF68; LA = *Lactobacillus acidophilus*; LABL = *Lactobacillus acidophilus* and *L. bulgaricus*; LABLa = *Lactobacillus acidophilus* and *Bifidobacterium longum*; LABLa = *Lactobacillus acidophilus* and *Bifidobacterium lactis*; BLST = *Bifidobacterium lactis* and *Streptococcus thermophilus*; LSFOS = *Lactobacillus sporogenes* and fructo-oligosaccharide; LABI = *Lactobacillus acidophilus* and *Bifidobacterium infantis*; Txt = treatment; Abx = antibiotic.

Quality: 1 = poor; 2 = fair; 3 = good (26).

\*Any gastrointestinal complaint including diarrhea.

**Table 2.** Meta-Analyses of Relative Risks Stratified by Type of Probiotic for the Prevention of Antibiotic Associated Diarrhea

Probiotic	Number of RCT	Combined RR	95% CI	<i>p</i> Value	Type of Model	References
<i>Saccharomyces boulardii</i>	6	0.37	0.26, 0.52	<0.0001	Fixed	(35–40)
<i>Lactobacillus rhamnosus</i> GG	6	0.31	0.13, 0.72	0.006	Random	(41–45)
Single strains of probiotics	6	0.46	0.21, 1.03	0.06	Random	(46–51)
Mixtures of two probiotics	7	0.51	0.38, 0.68	<0.0001	Fixed	(40, 47, 52–56)

Single strains included: *Clostridium butyricum* MIYAIRI; *Enterococcus faecium* SF68; *Lactobacillus acidophilus*; *Bifidobacterium longum*; *Bacillus clausii*; *Bifidobacterium lactis*; *Streptococcus thermophilus*; or *Lactobacillus sporogenes*.

Mixtures included: Lactinex = *L. acidophilus* and *L. bulgaricus*; *Lactobacillus acidophilus* and *Bifidobacterium lactis*; *Lactobacillus acidophilus* and *Bifidobacterium infantis*. *p* Value for null hypothesis that RR = 1.

probiotic was associated with a significant efficacy for AAD. Eight (67%) of 12 RCTs with a positive efficacy for AAD used a high daily dose of probiotic compared with only 2 (17%) of 12 RCTs that showed no significant difference yet used a high daily dose ( $p = 0.04$ ). The duration of probiotic treatment also varied widely from 5 days to 8 wk (median of 2 wk), but the duration of probiotic did not significantly differ in trials showing protective efficacy compared to no difference.

Data from 25 RCTs were combinable for a meta-analysis, as they reported frequencies of outcomes in treated and controls (35–56). As the  $\chi^2$  test for heterogeneity was 82.5 ( $p < 0.001$ ), indicating a low degree of homogeneity between studies, a random-effects model was utilized. The combined efficacy shows probiotics have a significant protective effect for AAD (Fig. 2). The relative risk for AAD was 0.43 (95% CI 0.31, 0.58),  $z = 5.4$ ,  $p < 0.001$ . A funnel plot (Fig. 3) may indicate the modest presence of some publication bias or may reflect the differences due to the type of probiotic. No significant evidence of publication bias was found using the Begg rank correlation test ( $z = -1.05$ ,  $p = 0.29$ ).

As the efficacy may vary by the probiotic strain being tested, additional meta-analyses were done, stratified *a priori* by the probiotic type. Two single probiotic strains showed significant efficacy for AAD: *S. boulardii* and *L. rhamnosus* GG (Table 2), as well as mixtures composed of two different types of probiotics. The meta-analysis for other single probiotic strain preparations than those above was not significantly protective for AAD, but as the strains were diverse, clinical conclusions should be made with caution.

**CDD.** Six RCTs provided adequate data regarding efficacy in a total of 354 patients with CDD, as shown in Table 3 (57–62). Of the six trials, two (33%) reported a significant reduction of CDD recurrences in the probiotic-treated group compared with the placebo group. Four studies did not reject the null hypothesis of no difference in the incidence of CDD recurrences for probiotic treated *versus* controls.

These contradictory results may be due to differences in the study population enrolled, the type of probiotic, the dose of probiotic given or the duration of treatment. All these trials were done in adults with prior antibiotic exposure and three studies were done exclusively in patients with recurrent CDD. The types of probiotics included *S. boulardii*, *L. rhamnosus* GG, *L. plantarum* 299v, and a mixture of *L. acidophilus* and *Bifidobacterium bifidum*. Five of the six RCTs

were treating patients with established CDD and the probiotic was combined with standard antibiotics (either vancomycin or metronidazole) for treating CDD. Unfortunately, the type or dose of the antibiotic was not randomized along with the probiotic arm for any of the studies. Daily doses of probiotics ranged from  $2 \times 10^{10}$  to  $6 \times 10^{11}$ , with a mean daily dose of  $5 \times 10^{10}$ . The duration of probiotic treatment also varied from 3 to 5 wk, with a median of 3 wk. The number of trials was too small to determine if a dose-response or duration-response effect was present.

Data from six RCTs were combinable for a meta-analysis, as they reported frequencies of outcome in treated and controls. As the  $\chi^2$  test for heterogeneity was 4.6 ( $p = 0.5$ ), indicating a high degree of homogeneity between studies, a fixed-effects model was utilized. The combined efficacy shows probiotics have a significant protective effect for CDD (Fig. 4). The relative risk for CDD was 0.59 (95% CI 0.41, 0.85),  $z = 2.8$ ,  $p = 0.005$ . A funnel plot (Fig. 5) indicates the absence of publication bias. No significant evidence of publication bias was found using the Begg rank correlation test ( $z = 0.56$ ,  $p = 0.57$ ).

Of the three different probiotics tested for the treatment of CDD, only *S. boulardii* showed significant reductions in recurrences of CDD (57, 58). *L. rhamnosus* GG and *L. plantarum* 299v did not show significant differences in CDD recurrence rates in probiotic *versus* control treated groups. The one trial testing a probiotic mixture (*L. acidophilus* and *B. bifidum*) for the prevention of CDD did not show significant efficacy (62).

#### Adverse Events

Twenty-six (84%) of the 31 trials presented data on adverse reactions, but five trials did not (35, 48, 52, 60, 62). In 24 trials, no adverse reactions were associated with the probiotic treatments. McFarland *et al.* reported significantly more subjects taking *S. boulardii* reported thirst (9%) or constipation (14%) compared with controls (57). Wullt *et al.* reported mild bloating (25%) or gas (37%) was associated with *L. rhamnosus* GG (60). No cases of bacteremia or fungemia or other serious adverse events were reported in the 31 RCTs.

#### COMMENT

Antibiotic-induced diseases present unique treatment challenges for the health-care provider. Treatment with additional

**Table 3.** Description of Six RCT of Probiotics for the Treatment or Prevention of *Clostridium difficile* Disease

N	Subjects	Probiotic	Probiotic Dose Per Day	Antibiotic Dose Per Day	Duration	Tx Duration	Follow-Up	Probiotic-Treated (recurred)		Control Group (recurred)		Quality	Weight	Reference
								No. Failed	No. Cured	No. Failed	No. Cured			
124	Adults CDD/RCDD	SB + V/M	$2 \times 10^{10}$	Varied	4 wk	4 wk	4 wk	15 (26)	42	30 (44.8)	37	3	51.5	(57)
32	Adults RCDD	SB + V	$2 \times 10^{10}$	2 g	4 wk	4 wk	4 wk	3 (16.7)	15	7 (50)	7	2	14.7	(58)
25	Adults CDD/RCDD	LGG + V or M	nr	nr	3 wk	3 wk	0	4 (36.4)	7	5 (35.7)	9	2	8.2	(59)
20	Adults RCDD	LP 299v + M	$5 \times 10^{10}$	nr	38 days	38 days	0	4 (36)	7	6 (67)	3	2	12.3	(60)
15	Adults RCDD	LGG + V or M	$6 \times 10^{11}$	Varied	3 wk	3 wk	4 wk	3 (37.5)	5	1 (14.3)	6	2	2.0	(61)
138	Inpatients varied antibiotics	LABB, no V or M	$2 \times 10^{10}$	None	20 days	20 days	0	2 (2.9)	67	6 (8.6)	63	3	11.2	(62)

N = number of subjects with evaluable outcome; SB = *Saccharomyces boulardii*; LGG = *Lactobacillus rhamnosus* GG; LP = *Lactobacillus plantarum* 299v; V = vancomycin; M = metronidazole, nr = not reported, LABB = *Lactobacillus acidophilus* and *Bifidobacterium bifidum*; nr = not reported; Quality: 1 = poor; 2 = fair; 3 = good (26).


antibiotics for diarrhea symptoms can worsen the condition by further disrupting the intestinal microflora. Efforts to prevent AAD by restricting antibiotic use in hospitals or reducing inappropriate antibiotic prescriptions has met with only limited success (63–65). Probiotics have shown promise in antibiotic mediated diseases as they are not disruptive of intestinal microflora and have multiple mechanisms of action in which to combat opportunistic pathogens *in situ* (12, 24). Acceptance of probiotics in routine formularies has been slow due to the lack of a consensus on the efficacy and safety of probiotics.

The result of the literature search on probiotics found that the majority of articles (54%) screened for inclusion were reviews or commentaries. Unfortunately, the prevalence of RCTs is not frequent in this area. Only 31 (17%) were included in this meta-analysis. This is the largest number of RCT analyzed by meta-analysis to date.

In this meta-analysis of 31 randomized, controlled trials, a clear message is seen supporting the use of probiotics for two antibiotic-associated diseases. Probiotics given for the prevention of AAD have a pooled relative risk of 0.43 (0.31, 0.58), using a random-effects model. This is similar to pooled estimates of risk from three earlier meta-analysis based on fewer (5–9) RCTs (16, 17, 66). D'Souza *et al.* pooled nine trials and found probiotics significantly reduced the odds of AAD (OR = 0.37, 95% CI 0.26, 0.52), but did not provide data on heterogeneity testing or publication bias (16). Cremonini *et al.* analyzed seven trials and found a pooled relative risk of 0.40 (95% CI 0.27, 0.57) (17). Although it was not stated if this was a random- or fixed-effects model, no significant heterogeneity was found ( $p = 0.42$ ) and no publication bias was seen in a funnel plot. Publication bias was not assessed by either Begg's or Egger's test in this meta-analysis. Szajewska and Mrukowicz analyzed five trials and found a pooled relative risk of 0.43 (95% CI 0.23, 0.78) using a random-effects model (66). No significant publication bias was found. However, this meta-analysis was restricted to one type of probiotic (*S. boulardii*) and did not examine other types of probiotics. These three meta-analyses were small and did not consistently provide full information on heterogeneity and publication bias. Despite these limitations, the three meta-analyses demonstrated a significant efficacy of probiotics for the prevention of AAD and validated our findings. The current meta-analysis included a large number of RCTs and fully described potential biases.

The etiologies of AAD are diverse and largely not identified. Approximately one-third of AAD is due to *C. difficile*, while another 10–20% is due to bacterial and viral etiologies (2). Of the 25 RCTs in this analysis, only 9 (36%) attempted to determine the etiologies of AAD in their trials. Only four trials reported treatment-specific efficacies stratified on *C. difficile* status and none were significant (36–38, 43). This is not surprising, as the original trials were powered for AAD and not *C. difficile* AAD. As the proportion of *C. difficile* is variable and may only account for one-third of the enrolled patients, trials for the prevention of *C. difficile* AAD typically






**Figure 3.** Funnel Plot of 25 randomized controlled trials of probiotics for antibiotic associated diarrhea. Dashed line indicates pooled relative risk of 0.43.

Heterogeneity between studies can be a limiting factor for meta-analyses. It may arise from differences in study populations, type of probiotic being investigated or differences in probiotic doses and duration of treatment. For AAD trials, the heterogeneity may be due to the different populations enrolled, as both adults and children given a variety of different types of antibiotics were studied. However, the efficacy was not found to differ for adult and pediatric subjects. For RCT involving CDD, all trials enrolled adults exposed to antibiotics.

Another source of heterogeneity for probiotic trials is the type of probiotic itself. Significant differences in effectiveness have been reported for different species and strains of similar species of bacteria and yeasts (24, 67, 68). Unfortunately, many trials only report the genus and species and




**Figure 5.** Funnel Plot of six randomized controlled trials of probiotics for *Clostridium difficile* associated disease. Dashed line indicates pooled relative risk of 0.59.

do not provide strain designations. A few studies (excluded from the analysis) even failed to provide the identity of the probiotic and only stated the treatment was “living yogurt” or “protective lactobacilli.” Future studies need to provide the complete identity of the probiotic being tested.

Trials for AAD failing to show significant efficacy may have used sub-therapeutic doses of probiotics (<10<sup>10</sup> organisms/day) or failed to provide the probiotic during the entire period of susceptibility when normal intestinal microflora is becoming reestablished (usually 6–8 wk) (2). This meta-analysis found a dose-response for probiotics used to prevent AAD. Trials for the treatment of CDD were more homogeneous in terms of probiotic treatments than trials for AAD. Probiotic doses and durations were similar (100% of those reporting doses used >10<sup>10</sup>/day) and all studies treated patients for at least 3 wk.

Another limitation in these trials was the lack of standardization when a combination treatment regimen was used. The common strategy for treating CDD infections is to combine the investigational probiotic with one of the standard antibiotics (vancomycin or metronidazole) given to treat *C. difficile*. The hypothesis of the combination therapy is that the antibiotic kills vegetative *C. difficile* organisms in the intestine, which would clear the pathogenic toxins, and the probiotic would assist in reestablishing the protective intestinal microflora so that when residual spores germinate, colonization is rebuffed by the newly restored microflora barrier. Unfortunately, only the probiotic component of these trials was randomized. The standard antibiotic varied by type and dose and was not controlled in most trials. This is an important consideration because Surawicz *et al.* found only a high dose of vancomycin (2 g/day) completely cleared *C. difficile* toxins by the end of 10 days of therapy, whereas a lower dose (500 mg/day) of vancomycin failed to clear toxins in 10% and metronidazole (1.5 g/day) only cleared toxins in 40% of the patients (58). Future studies should randomize the combination treatment with a standard dose of both the



**Figure 4.** Forest Plot of six randomized controlled trials of probiotics for the treatment of *Clostridium difficile* disease showing crude and pooled risk ratios. SB = *Saccharomyces boulardii*; LGG = *Lactobacillus rhamnosus* GG; LP = *Lactobacillus plantarum* 299v; LA = *Lactobacillus acidophilus*; BB = *Bifidobacterium bifidum*.

standard antibiotic and the probiotic to test the complete regimen.

Potential biases in review process may be due to publication bias. Sutton *et al.* reviewed 48 meta-analyses and found 30 (63%) made no reference to publication bias or reported funnel plots (69). In this meta-analysis, publication bias was minimized by conducting extensive searches through multiple databases and receiving original data from the authors. Funnel plots for AAD and CDD showed there may be some publication bias present for AAD, but the discovery of numerous negative trials for AAD may have minimized this bias. Selection and ascertainment bias was minimized by including only RCTs with validated outcomes.

Concerns about the safety of probiotics have been raised. As probiotics are living organisms given to ill patients, the potential for adverse reactions exists. Some intestinal bacteria have been shown to translocate from the intestine to other organs and antibiotic-resistance gene acquisition also is a potential concern. These two problems have yet to be observed in clinical trials using probiotics. Although case reports and case series of bacteremia and fungemia have been reported in the literature, no incidents occurred in patients enrolled in the 31 RCTs reviewed for this meta-analysis (70, 71). Caution should be exercised for patients who are severely ill and receiving nutrition or antibiotics through a potentially open portal (catheter or nasogastric tube). Infrequent blood-stream infections have been reported, most probably due to contamination of the environment as the probiotic capsule is opened at bedside and mixed with food (72). Rare complications including endocarditis and liver abscess have been associated with *L. rhamnosus* use (73, 74). Bacteremia and fungemia have been associated with probiotics, but respond well to antibiotics or anti-fungal medications (75–78).

Considering that millions of doses of probiotics are taken per year globally, the risk of complications due to probiotics is extremely low. However, prolonged safety issues have not been addressed in studies.

## CONCLUSION

In summary, the present meta-analyses suggest that probiotics can significantly reduce the incidence of AAD and are an effective treatment for CDD. Future studies should expand the types of probiotics tested and pay careful attention to proper study design and sample size considerations.

## ACKNOWLEDGMENT

The author had full access to all of the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. The author also would like to acknowledge the participants in these trials; without their

willingness to volunteer, scientific discoveries would not be made.

## STUDY HIGHLIGHTS

### What Is Current Knowledge

- Treatment strategies for diseases that involve the disruption of intestinal microflora by antibiotics may be particularly effective when probiotics are used.
- Studies of the efficacy of probiotics in *C. difficile* colitis are conflicting and a consensus has yet to be reached.

### What Is New Here

- This meta-analysis pooled together 31 randomized controlled trials to determine if probiotics are efficacious overall for these types of diseases.
- Three different probiotics (*Saccharomyces boulardii*, *Lactobacillus rhamnosus* GG and probiotic mixtures) helped prevent antibiotic-associated diarrhea but only *S. boulardii* appeared useful for *Clostridium difficile* disease.

**Reprint requests and correspondence:** Lynne McFarland, Ph.D., Department of Health Services Research and Development, VA Puget Sound Health Care System, S-152, Metropolitan Park West, 1100 Olive Way, Suite 1400, Seattle, WA 98101.

Received August 24, 2005; accepted November 4, 2005.

## REFERENCES

1. Levy DG, Stergachis A, McFarland LV, et al. Antibiotics and *Clostridium difficile* diarrhea in the ambulatory care setting. *Clin Ther* 2000;22:91–102.
2. McFarland LV. Epidemiology, risk factors and treatments for antibiotic-associated diarrhea. *Dig Dis* 1998;16:292–307.
3. Winston DJ, Ho WG, Bruckner DA, et al. Beta-lactam antibiotic therapy in febrile granulocytopenic patients. A randomized trial comparing cefoperazone plus piperacillin, cef-tazidime plus piperacillin, and imipenem alone. *Ann Intern Med* 1991;115:849–59.
4. Ackermann G, Thomalla S, Achermann F, et al. Prevalence and characteristics of bacteria and host factors in an outbreak situation of antibiotic-associated diarrhea. *J Med Microbiol* 2005;54(Pt 2):149–53.
5. McFarland LV. Normal flora: Diversity and functions. *Microb Ecol Health Dis* 2000;12:193–207.
6. Pepin J, Valiquette L, Alary ME, et al. *Clostridium difficile*-associated diarrhea in a region of Quebec from 1991 to 2003: A changing pattern of disease severity. *J Ayub Med Coll Abbottabad* 2004;171:466–72.
7. Al-Eidan, McElnay JC, Schott MG, et al. *Clostridium difficile*-associated diarrhoea in hospitalized patients. *J Clin Pharm Ther* 2000;25:101–9.
8. Kyne L, Hamel MB, Polavaram R, et al. Health care costs and mortality associated with nosocomial diarrhea due to *Clostridium difficile*. *Clin Infect Dis* 2002;34:346–53.
9. McFarland LV, Surawicz CM, Rubin M, et al. Recurrent *Clostridium difficile* disease: Epidemiology and clinical

- characteristics. *Infect Control Hosp Epidemiol* 1999;20:43–50.
10. Miller MA, Hyland M, Ofner-Agostini M, et al. Canadian Hospital Epidemiology Committee. Morbidity, mortality, and healthcare burden of nosocomial *Clostridium difficile*-associated diarrhea in Canadian hospitals. *Infect Control Hosp Epidemiol* 2002;23:137–40.
  11. Oldfield EC. *Clostridium difficile*-associated diarrhea: Risk factors, diagnostic methods and treatment. *Rev Gastroenterol Disord* 2004;4(4):186–95.
  12. McFarland LV. A review of the evidence of health claims for biotherapeutic agents. *Microb Ecol Health Dis* 2000;12:65–76.
  13. Qamar A, Aboudola S, Warny M, et al. *Saccharomyces boulardii* stimulates intestinal immunoglobulin A immune response to *Clostridium difficile* toxin A in mice. *Infect Immun* 2001;69:2762–5.
  14. Elmer GW. Probiotics: “Living drugs.” *Am J Health Syst Pharm* 2001;58:1101–9.
  15. Katikireddi V. UK launches inquired into *Clostridium difficile* outbreak. *J Ayub Med Coll Abbottabad* 2005;173(2):138.
  16. D’Souza AL, Rajkumar C, Cooke J, et al. Probiotics in prevention of antibiotic associated diarrhoea: Meta-analysis. *BMJ* 2002;324:1361.
  17. Cremonini F, Di Caro S, Nista EC, et al. Meta-analysis: The effect of probiotic administration on antibiotic-associated diarrhoea. *Aliment Pharmacol Ther* 2002;16:1461–7.
  18. Bricker E, Garg R, Nelson R, et al. Antibiotic treatment for *Clostridium difficile*-associated diarrhea in adults. *Cochrane Database Syst Rev* 2005;25(1):CD004610.
  19. McFarland LV, Surawicz CM. *Clostridium difficile* disease: Diagnosis and treatment. In: McDonald JWD, Burroughs AK, Feagan BG, eds. *Evidence based gastroenterology and hepatology*, 2nd Ed. London: BMJ Books, 2004. Chapter 18: 285–301.
  20. Shaw RL, Booth A, Sutton AJ, et al. Finding qualitative research: An evaluation of search strategies. *BMC Med Res Methodol* 2004;4:5–9.
  21. Egger M, Smith GD, Phillips AN. Meta-analysis: Principles and procedures. *BMJ* 1997;315:1533–7.
  22. Moher D, Cook DJ, Eastwood S, et al. Improving the quality of reports of meta-analyses of randomized controlled trials: The QUOROM statement. QUOROM Group. *Br J Surg* 2000;87(11):1448–54.
  23. Stroup DF, Berlin JA, Morton SC, et al. Meta-analysis of observational studies in epidemiology: A proposal for reporting. *JAMA* 2000;283:2008–12.
  24. McFarland LV, Elmer GM. Properties of evidence-based probiotics for human health. In: Goklepe I, Juneja V eds. *Probiotics in food safety and human health*: New York Marcel Dekker, Inc, 2005:109–37.
  25. Surawicz CM. Antibiotic-associated diarrhea and pseudomembranous colitis: Are they less common with poorly absorbed antimicrobials? *Chemotherapy* 2005;51(suppl 1):81–9.
  26. Harris RP, Helfand M, Woolf SH, et al. Current methods of the U.S. Preventive Services Task Force: A review of the process. *Am J Prev Med* 2001;20(suppl 3):21–35.
  27. Juni P, Altman DG, Egger M. Systematic reviews in health care: Assessing the quality of controlled clinical trials. *BMJ* 2001;323:42–6.
  28. DerSimonian R, Laird N. Meta-analysis in clinical trials. *Control Clin Trials* 1986;7(3):177–88.
  29. Egger M, Smith GD, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. *BMJ* 1997;315:629–34.
  30. Begg CB, Mazumdar M. Operating characteristics of a rank correlation test for publication bias. *Biometrics* 1994;50(4):1088–101.
  31. Beniwal RS, Arena VC, Thomas L, et al. A randomized trial of yogurt for prevention of antibiotic-associated diarrhea. *Dig Dis Sci* 2003;48:2077–82.
  32. Ahuja M, Khamar B. Antibiotic associated diarrhea: A controlled study comparing plain antibiotic with those containing protected Lactobacilli. *J Indian Med Assoc* 2002;100(5):334–5.
  33. Lewis S, Burmeister S, Cohen S, et al. Failure of dietary oligofructose to prevent antibiotic-associated diarrhea. *Aliment Pharmacol Ther* 2005;21:469–77.
  34. Lewis S, Burmeister S, Brazier J. Effect of the prebiotic oligofructose on relapse of *Clostridium difficile*-associated diarrhea: A randomized, controlled study. *Clin Gastroenterol Hepatol* 2005;3:442–8.
  35. Adam J, Barret C, Barret-Bellet A, et al. Controlled double-blind clinical trials of Ultra-Levure: Multicentre study by 25 physicians in 388 cases. *Gaz Med Fr* 1977;84:2072–8.
  36. Surawicz CM, Elmer GW, Speelman P, et al. Prevention of antibiotic-associated diarrhea by *Saccharomyces boulardii*—A prospective-study. *Gastroenterology* 1989;96:981–8.
  37. McFarland LV, Surawicz CM, Greenberg RN, et al. Prevention of beta-lactam-associated diarrhea by *Saccharomyces boulardii* compared with placebo. *Am J Gastroenterol* 1995;90:439–48.
  38. Kotowska M, Albrecht P, Szajewska H. *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhoea in children: A randomized double-blind placebo-controlled trial. *Aliment Pharmacol Ther* 2005;21:583–90.
  39. Lewis SJ, Potts LF, Barry RE. The lack of therapeutic effect of *Saccharomyces boulardii* in the prevention of antibiotic-related diarrhoea in elderly patients. *J Infect* 1998;36:171–4.
  40. Cremonini F, Di Caro S, Covino M, et al. Effect of different probiotic preparations on anti-*Helicobacter pylori* therapy-related side effects: A parallel group, triple blind, placebo-controlled study. *Am J Gastroenterol* 2002;97(11):2744–9.
  41. Arvola T, Laiho K, Torkkeli S, et al. Prophylactic *Lactobacillus GG* reduces antibiotic-associated diarrhea in children with respiratory infections: A randomized study. *Pediatrics* 1999;104:e64.
  42. Vanderhoof JA, Whitney DB, Antonson DL, et al. *Lactobacillus GG* in the prevention of antibiotic-associated diarrhea in children. *J Pediatr* 1999;135:564–8.
  43. Szajewska H, Kotowska M, Mrukowicz JZ, et al. Efficacy of *Lactobacillus GG* in prevention of nosocomial diarrhea in infants. *J Pediatr* 2001;138:361–5.
  44. Thomas MR, Litin SC, Osmon DR, et al. Lack of effect of *Lactobacillus GG* on antibiotic-associated diarrhea: A randomized, placebo-controlled trial. *Mayo Clin Proc* 2001;76:883–9.
  45. Armuzzi A, Cremonini F, Ojetti V, et al. Effect of *Lactobacillus GG* supplementation on antibiotic-associated gastrointestinal side effects during *Helicobacter pylori* eradication therapy: A pilot study. *Digestion* 2001;63:1–7.
  46. Nista EC, Candelli M, Cremonini F, et al. *Bacillus clausii* therapy to reduce side-effects of anti-*Helicobacter pylori* treatment: Randomized, double-blind, placebo controlled trial. *Aliment Pharmacol Ther* 2004;20:1181–8.
  47. Orrhage K, Brismar B, Nord CE. Effects of supplements of *Bifidobacterium longum* and *Lactobacillus acidophilus* on the intestinal microbiota during administration of clindamycin. *Microb Ecol Health Dis* 1994;7:17–25.
  48. Seki H, Shiohara M, Matsumura T, et al. Prevention of antibiotic-associated diarrhea in children by

- Clostridium butyricum* MIYAIRI. *Pediatr Int* 2003;45:86–90.
49. Wunderlich PF, Braun L, Fumagalli I, et al. Double-blind report on the efficacy of lactic acid-producing *Enterococcus* SF68 in the prevention of antibiotic-associated diarrhoea and in the treatment of acute diarrhoea. *J Int Med Res* 1989;17:333–8.
  50. Borgia M, Sepe N, Brancato V, et al. A controlled clinical study on *Streptococcus faecium* preparation for the prevention of side reactions during long term antibiotic treatments. *Curr Ther Res* 1982;31:265–71.
  51. Witsell DL, Garrett G, Yarbrough WG, et al. Effect of *Lactobacillus acidophilus* on antibiotic-associated gastrointestinal morbidity: A prospective randomized trial. *J Otolaryngol* 1995;24:231–3.
  52. Gotz V, Romankiewicz JA, Moss J, et al. Prophylaxis against ampicillin-associated diarrhea with a *Lactobacillus* preparation. *Am J Hosp Pharm* 1979;36:754–7.
  53. Tankanow RM, Ross MB, Ertel IJ, et al. A double-blind, placebo-controlled study of the efficacy of Lactinex in the prophylaxis of amoxicillin-induced diarrhea. *DICP* 1990;24:382–4.
  54. Correa NB, Filho P, Luciano A, et al. A randomized formula controlled trial of *Bifidobacterium lactis* and *Streptococcus thermophilus* for prevention of antibiotic-associated diarrhea in infants. *J Clin Gastroenterol* 2005;39:385–9.
  55. LaRosa M, Bottaro G, Gulino N, et al. Prevention of antibiotic-associated diarrhea with *Lactobacillus sporogens* and fructo-oligosaccharides in children. A multicentric double-blind vs placebo study. *Minerva Pediatr* 2003;55(5):447–52.
  56. Jirapinyo P, Thamonsiri N, Densupsoontorn N, et al. Prevention of antibiotic-associated diarrhea in infants by probiotics. *J Med Assoc Thai* 2002;85(suppl 2):S739–42.
  57. McFarland LV, Surawicz CM, Greenberg RN, et al. A randomized placebo-controlled trial of *Saccharomyces boulardii* in combination with standard antibiotics for *Clostridium difficile* disease. *JAMA* 1994;271:1913–8.
  58. Surawicz CM, McFarland LV, Greenberg RN, et al. The search for a better treatment for recurrent *Clostridium difficile* disease: Use of high-dose vancomycin combined with *Saccharomyces boulardii*. *Clin Infect Dis* 2000;31:1012–7.
  59. Pochapin M. The effect of probiotics on *Clostridium difficile* diarrhea. *Am J Gastroenterol* 2000;95:S11–13.
  60. Wullt M, Hagglatt ML, Odenholt I. *Lactobacillus plantarum* 299v for the treatment of recurrent *Clostridium difficile*-associated diarrhoea: A double-blind, placebo-controlled trial. *Scand J Infect Dis* 2003;35:365–7.
  61. Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent *Clostridium difficile* disease. *J Med Microbiol* 2005;54(Pt 9):905–6.
  62. Plummer S, Weaver MA, Harris JC, et al. *Clostridium difficile* pilot study: Effects of probiotic supplementation on the incidence of *Clostridium difficile* diarrhoea. *Int Microbiol* 2004;7:59–62.
  63. Belongia EA, Knobloch MH, Kieke BA, et al. Impact of statewide program to promote appropriate antimicrobial drug use. *Emerg Infect Dis* 2005;11(6):912–20.
  64. Gul YA, Hong LC, Prasannan S. Appropriate antibiotic administration in elective surgical procedures: Still missing the message. *Asian J Surg* 2005;28(2):104–8.
  65. Berild D, Smaabrekke L, Halvorsen DS, et al. *Clostridium difficile* infections related to antibiotic use and infection control facilities in two university hospitals. *J Hosp Infect* 2003;54(3):202–6.
  66. Szajewski H, Mrukowicz J. Meta-analysis: Non-pathogenic yeast *Saccharomyces boulardii* in the prevention of antibiotic-associated diarrhea. *Aliment Pharmacol Ther* 2005;22:365–72.
  67. Morelli L, Zonenschain D, Callegari ML, et al. Assessment of a new synbiotic preparation in health volunteers: Survival, persistence of probiotic strains and its effect on the indigenous flora. *Nutr J* 2003;2:11–6.
  68. Dunne C, O'Mahony L, Murphy L, et al. *In vitro* selection criteria for probiotic bacteria of human origin: Correlation with *in vivo* findings. *Am J Clin Nutr* 2001;73:386S–92S.
  69. Sutton AJ, Duval SJ, Tweedie RL, et al. Empirical assessment of effect of publication bias on meta-analysis. *BMJ* 2000;320:1574–7.
  70. DeGroote MA, Frank DN, Dowell E, et al. *Lactobacillus rhamnosus* GG bacteremia associated with probiotic use in a child with short gut syndrome. *Pediatr Infect Dis J* 2005;24(3):278–80.
  71. Young RJ, Vanderhoof JA. Two cases of *Lactobacillus* bacteremia during probiotic treatment of short gut syndrome. *J Pediatr Gastroenterol Nutr* 2004;39(4):436–7.
  72. Hennequin C, Kauffmann-Lacroix C, Jobert A, et al. Possible role of catheters in *Saccharomyces boulardii* fungemia. *Eur J Clin Microbiol Infect Dis* 2000;19:16–20.
  73. Rautio M, Jousimies-Somer H, Kauma H, et al. Liver abscess due to a *Lactobacillus rhamnosus* strain indistinguishable from *L. rhamnosus* strain GG. *Clin Infect Dis* 1999;28:1159–60.
  74. Sipsas NV, Zonios DI, Kordossis T. Safety of *Lactobacillus* strains used as probiotic agents. *Clin Infect Dis* 2002;34:1283–4.
  75. Munoz P, Bouza E, Cuenca-Estrella M, et al. *Saccharomyces cerevisiae* fungemia: An emerging infectious disease. *Clin Infect Dis* 2005;40:1625–34.
  76. Salminen MK, Rautelin H, Tynkkynen S, et al. *Lactobacillus* bacteremia, clinical significance, and patient outcome, with special focus on probiotic *L. rhamnosus* GG. *Clin Infect Dis* 2004;38:62–9.
  77. Land MH, Rouster-Stevens K, Woods CR, et al. *Lactobacillus sepsis* associated with probiotic therapy. *Pediatrics* 2005;115(1):178–81.
  78. Surawicz CM, McFarland LV. Risks of biotherapeutic agents. In: Elmer GW, McFarland LV, Surawicz CM, eds. *Biotherapeutic agents and infectious diseases*. Totowa, NJ: Humana Press, 1999:263–8.